Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. BRKR
BRKR logo

BRKR Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
37.130
Open
36.580
VWAP
36.86
Vol
178.37K
Mkt Cap
5.57B
Low
36.470
Amount
6.58M
EV/EBITDA(TTM)
14.63
Total Shares
152.22M
EV
7.20B
EV/OCF(TTM)
53.54
P/S(TTM)
1.62
Bruker Corporation is a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic. Its segments include Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies (BEST). BSI segment designs, manufactures and distributes life science tools based on magnetic resonance technology and offers automated laboratory research. BSI CALID segment designs, manufactures and distributes life science mass spectrometry, applied spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions. BSI NANO designs, manufactures and distributes advanced x-ray instruments, atomic force microscopy instrumentation, and fluorescence optical microscopy instruments. BEST segment develops and manufactures superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare and energy physics research.
Show More

Events Timeline

(ET)
2026-02-12
07:30:00
Company Expects FY26 Revenue of $3.57B to $3.6B
select
2026-02-12
07:30:00
Bruker Reports Q4 Revenue of $977.2M, Exceeding Expectations
select
2026-02-09 (ET)
2026-02-09
07:20:00
Bruker Corporation Launches iNTApharma Platform
select

News

NASDAQ.COM
2.0
03-06NASDAQ.COM
Bruker Corp Shares Enter Oversold Territory
  • Oversold Signal: Bruker Corp (Ticker: BRKR) entered oversold territory on Friday with an RSI reading of 29.5, hitting a low of $36.515 per share, indicating that recent heavy selling may be exhausting, thus presenting potential buying opportunities for investors.
  • Market Comparison: Compared to the S&P 500 ETF (SPY) with an RSI of 41.2, BRKR's 29.5 RSI suggests relative weakness, which may attract investors looking for rebounds, especially amid increasing market volatility.
  • Historical Performance Analysis: BRKR's 52-week low is $28.53 and high is $56.22, with the last trade at $36.68, reflecting significant price fluctuations over the past year, prompting investors to monitor future price movements closely.
  • Investor Strategy: Given BRKR's oversold condition, investors may seek suitable entry points, particularly if market sentiment shifts positively, potentially providing support for future stock price rebounds.
Newsfilter
3.5
02-23Newsfilter
Bruker Unveils New Spatial Biology Platforms at AGBT 2026
  • Portfolio Innovations: Bruker Corporation announced significant advancements at the 2026 AGBT meeting, including the launch of the CellScape XR spatial proteomics platform and the unique CosMx mouse whole transcriptome panel, reinforcing its leadership in spatial biology and accelerating scientific discovery and translational research.
  • PaintScape Pre-Orders: The company is now accepting pre-orders for the PaintScape system, the first high-precision platform enabling multiplexed, direct visualization of the 3D genome in single cells, with shipments expected to begin this spring, allowing researchers to explore the relationship between genome structure and disease biology.
  • CellScape XR Performance Enhancements: The next-generation CellScape XR platform integrates major advancements in instrumentation, software, and assay ecosystems, significantly improving data quality and throughput, which is expected to enhance clinical applications and help customers achieve greater impact in their scientific endeavors.
  • GeoMx DSP Multiomics Platform: Bruker's GeoMx Digital Spatial Profiler enables large-scale spatial biomarker discovery with over 1,200 protein targets, showcasing its extensive application potential in oncology and neuroscience, further advancing research in spatial biology.
Barron's
4.0
02-19Barron's
The Dollar's Dominance Is Winding Down: Strategies for Investors.
  • Dollar Decline: The dollar is experiencing a decline, impacting investors' strategies and expectations.
  • Investor Adaptation: Investors need to adjust to the changing economic landscape and find ways to navigate the challenges posed by a weaker dollar.
Benzinga
9.5
02-13Benzinga
Bruker Corp Reports Mixed Q4 Financial Results
  • Earnings Performance: Bruker reported Q4 earnings of $0.59 per share, missing the analyst consensus of $0.65, indicating pressure on profitability that may affect investor confidence.
  • Sales Beat Expectations: The company achieved quarterly sales of $977.2 million, surpassing the analyst estimate of $960.834 million, suggesting strong market demand that could bolster future performance expectations.
  • Future Outlook: Bruker projects FY2026 adjusted EPS between $2.10 and $2.15, slightly below the market estimate of $2.13, reflecting a cautious stance on future profit growth.
  • Analyst Rating Adjustments: Barclays analyst maintained an Overweight rating on Bruker but lowered the price target from $55 to $50, indicating a cautious outlook on the company's future performance.
seekingalpha
9.5
02-12seekingalpha
Bruker Corporation Q4 2025 Earnings Call Insights
  • Revenue Exceeds Expectations: Bruker Corporation reported Q4 2025 revenues of $977.2 million, approximately $20 million above guidance, demonstrating the company's resilience in the face of challenges such as academic funding pressures, tariffs, and currency fluctuations.
  • Strong Free Cash Flow: The company achieved free cash flow of $207.3 million in Q4, an increase of about $54 million year-over-year, reflecting improved working capital performance despite capital expenditures of $22.6 million, thereby enhancing financial flexibility.
  • 2026 Guidance: Bruker anticipates reported revenue growth of 4% to 5% for 2026, alongside a targeted operating profit margin improvement of 250 to 300 basis points, despite a 50 basis point currency headwind, indicating management's confidence in future growth prospects.
  • Innovation-Driven Growth: Management highlighted strong initial demand for several new product launches in 2025, which are expected to drive revenue growth in 2026 and beyond, particularly in spatial biology, where orders increased by 25% year-over-year, reflecting market acceptance of new technologies.
moomoo
9.5
02-12moomoo
BRUKER STOCK FALLS 12% FOLLOWING Q4 EARNINGS DISAPPOINTMENT
  • Company Performance: Shares of Bruker have decreased by 12% following a profit miss in the fourth quarter.
  • Market Reaction: The decline in share value reflects investor concerns over the company's financial performance and outlook.
Wall Street analysts forecast BRKR stock price to rise
12 Analyst Rating
Wall Street analysts forecast BRKR stock price to rise
7 Buy
4 Hold
1 Sell
Moderate Buy
Current: 0.000
sliders
Low
40.00
Averages
52.18
High
60.00
Current: 0.000
sliders
Low
40.00
Averages
52.18
High
60.00
Citi
Patrick Donnelly
Neutral
downgrade
$53 -> $40
AI Analysis
2026-02-13
Reason
Citi
Patrick Donnelly
Price Target
$53 -> $40
AI Analysis
2026-02-13
downgrade
Neutral
Reason
Citi analyst Patrick Donnelly lowered the firm's price target on Bruker to $40 from $53 and keeps a Neutral rating on the shares.
TD Cowen
Hold
downgrade
$53 -> $43
2026-02-13
Reason
TD Cowen
Price Target
$53 -> $43
2026-02-13
downgrade
Hold
Reason
TD Cowen lowered the firm's price target on Bruker to $43 from $53 and keeps a Hold rating on the shares. The firm said they reported disappointing Q4 earnings, margins and free cash flow while offering a very weak guida, leaving a steep ramp needed to reach the 2026 guidance.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for BRKR
Unlock Now

Valuation Metrics

The current forward P/E ratio for Bruker Corp (BRKR.O) is 24.05, compared to its 5-year average forward P/E of 26.53. For a more detailed relative valuation and DCF analysis to assess Bruker Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
26.53
Current PE
24.05
Overvalued PE
33.22
Undervalued PE
19.84

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
17.57
Current EV/EBITDA
14.96
Overvalued EV/EBITDA
20.99
Undervalued EV/EBITDA
14.16

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
3.28
Current PS
2.12
Overvalued PS
4.29
Undervalued PS
2.27

Financials

AI Analysis
Annual
Quarterly

Whales Holding BRKR

N
Needham Investment Management, LLC
Holding
BRKR
+19.84%
3M Return
V
Vaughan Nelson Investment Management, L.P.
Holding
BRKR
-0.35%
3M Return
E
Eversept Partners, L.P.
Holding
BRKR
-0.87%
3M Return
O
Orbis Investment Management Limited
Holding
BRKR
-2.67%
3M Return
P
Pallas Capital Advisors LLC
Holding
BRKR
-9.23%
3M Return
S
Samlyn Capital, LLC
Holding
BRKR
-10.48%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Bruker Corp (BRKR) stock price today?

The current price of BRKR is 36.99 USD — it has increased 1.07

What is Bruker Corp (BRKR)'s business?

Bruker Corporation is a developer, manufacturer and distributor of high-performance scientific instruments and analytical and diagnostic. Its segments include Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies (BEST). BSI segment designs, manufactures and distributes life science tools based on magnetic resonance technology and offers automated laboratory research. BSI CALID segment designs, manufactures and distributes life science mass spectrometry, applied spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions. BSI NANO designs, manufactures and distributes advanced x-ray instruments, atomic force microscopy instrumentation, and fluorescence optical microscopy instruments. BEST segment develops and manufactures superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare and energy physics research.

What is the price predicton of BRKR Stock?

Wall Street analysts forecast BRKR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRKR is52.18 USD with a low forecast of 40.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Bruker Corp (BRKR)'s revenue for the last quarter?

Bruker Corp revenue for the last quarter amounts to 977.20M USD, decreased -0.24

What is Bruker Corp (BRKR)'s earnings per share (EPS) for the last quarter?

Bruker Corp. EPS for the last quarter amounts to 0.10 USD, increased 11.11

How many employees does Bruker Corp (BRKR). have?

Bruker Corp (BRKR) has 11085 emplpoyees as of March 11 2026.

What is Bruker Corp (BRKR) market cap?

Today BRKR has the market capitalization of 5.57B USD.